A.A. Zilfyan

[104] The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.

[105] Heijl A, Leske MC, Bengtsson B. Hyman L, Bengtsson B, Hussein M, early manifest glaucoma trial group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002; 120:

[106] Baker PS, Brown GC. Stem-cell therapy in retinal disease. Curr Opin Ophthalmol

[107] Tibbetts MD, Samuel MA, Chang TS. Ho AC. Stem-cell therapy for retinal disease.

[108] Schwartz SD, Hubschman JP, Heilwell G. Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem-cell trials for macular

[109] Boucherie C, Sowden JC, Ali RR. Induced pluripotent stem cell technology for gener‐

[110] Tucker BA, Park IH, Qi SD. Klassen HJ, Jiang C, Yao J, Redenti S, Daley GQ, Young MJ. Transplantation of adult mouse iPS cell derived photoreceptor precursors re‐ stores retinal structure and function in degenerative mice. PLoS One 2011; 6: e18992.

[111] Zhou L, Wang W, Liu Y. Fenandez de Castro J, Ezashi T, Telugu BP, Roberts RM, Ka‐ plan HJ, dean DC. Differentiation of induced pluripotent stem cells of swine into rod photoreceptors and their integration into the retina. Stem Cells 2011; 29: 972-980.

degeneration: a preliminary report. Lancet 2012; 379: 713-720.

ating photoreceptors. Regen Med 2011; 6: 469-479.

Am J Ophthalmol 2000; 130: 429-440.

Curr Opin Ophthalmol 2012; 23: 226-234.

1268-1279.

74 Glaucoma - Basic and Clinical Aspects

2009; 20: 175-181.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/55037
